Start Chat

Chat online with a DermiraConnect support specialist here Or call us at 1-877-DERMIRA (1-877-337-6472)
(Monday to Friday, 8 am-8 pm EST)

By clicking "Start Chat," you acknowledge that your web chat conversations may be stored by Dermira for quality assurance only, so that we can improve your web experience. In the event that your conversation includes mention of potential adverse events while using QBREXZA your information will be provided to Dermira Medical Information for additional support related to the event.

DermiraConnect empowers your patients to start and remain on QBREXZA

DermiraConnect is a patient services program made simple. This self-guided program provides patients with the support they need when they need it, and helps you keep the focus on managing their treatment.

Confidence in affordability

Patients can manage their out-of-pocket costs with the QBREXZA Savings Card:

$35 Patients with commercial insurance may pay as little as $35 per fill.*†‡


Visit with your patient to download a savings card
Confidence in fulfillment
Learn more about e-prescribing QBREXZA

Information to assist with prior authorizations
Powered by our partnerships with Foundation Care and CoverMyMeds, DermiraConnect can assist your practice with prior authorizations and appeals. Explore our suite of office resources below for forms, letters and other information to assist your patients in their QBREXZA journey.

If a prior authorization is required, please note that the ICD-10 code for diagnosis of primary axillary hyperhidrosis is L74.510.

Confidence in adherence support

DermiraConnect can help your patients stay on QBREXZA and get the most out of their therapy:

Refill reminders
  • Our pharmacy partner Foundation Care can stay in touch each month with refill reminders
News and updates from QBREXZA Patient Self-Service: Checking their QBREXZA Savings Card balance
  • Our self-service site lets your patients:
    • Check their card balance
    • View their prescription fill history

*Depending on eligibility and status of coverage. See terms and conditions.

One prescription fill=a 30-day supply (30 pouches).

The QBREXZA™ (glycopyrronium) cloth Savings Card is valid for patients with commercial insurance or patients who have no insurance. Patients enrolled in Medicare, Medicaid, Medigap, TRICARE, the Department of Veterans Affairs healthcare program, or any other federal or state government-funded healthcare program ("Government Programs") are not eligible. Patients who become enrolled in such Government Programs during their enrollment period will no longer be eligible for the program. Eligible patients must be residents of the United States, and the patient, or the patient's parent or guardian, must be 18 years or older to receive QBREXZA Savings Card assistance.

For questions regarding setup, claim transmission, patient eligibility, or other issues, call LoyaltyScript® for QBREXZA program at 1-877-DERMIRA Monday-Friday, 8 am-8 pm EST.

Dermira, Inc., reserves the right to rescind, revoke, or amend this offer at any time.


QBREXZA is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.


Contraindications: QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren’s syndrome).


Worsening of Urinary Retention: QBREXZA should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Instruct patients to discontinue use immediately and consult a physician should any of these signs or symptoms develop. Patients with a history of urinary retention were not included in the clinical studies.

Control of Body Temperature: In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

Operating Machinery or an Automobile: Transient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.


The most common adverse reactions seen in ≥2% of subjects treated with QBREXZA were dry mouth (24.2%), mydriasis (6.8%), oropharyngeal pain (5.7%), headache (5.0%), urinary hesitation (3.5%), vision blurred (3.5%), nasal dryness (2.6%), dry throat (2.6%), dry eye (2.4%), dry skin (2.2%) and constipation (2.0%). Local skin reactions, including erythema (17.0%), burning/stinging (14.1%) and pruritus (8.1%) were also common.


Anticholinergics: Coadministration of QBREXZA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of QBREXZA with other anticholinergic-containing drugs.


Instruct patients to use one cloth to apply QBREXZA to both axillae by wiping the cloth across one underarm, ONE TIME. Using the same cloth, apply the medication to the other underarm, ONE TIME. Inform patients that QBREXZA can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.

Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.


Pregnancy: There are no available data on QBREXZA use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

Lactation: There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QBREXZA and any potential adverse effects on the breastfed infant from QBREXZA or from the underlying maternal condition.

Renal Impairment: The elimination of glycopyrronium is severely impaired in patients with renal failure.

Please see Full Prescribing Information.